{"id":"metformin-up-titration","safety":{"commonSideEffects":[{"rate":"20–30","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)"},{"rate":"3–5","effect":"Metallic taste"},{"rate":"10–30","effect":"Vitamin B12 deficiency"},{"rate":"<0.1","effect":"Lactic acidosis (rare, in renal impairment)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin is a biguanide that primarily works by decreasing gluconeogenesis in the liver and improving peripheral glucose uptake and utilization. It also enhances insulin sensitivity and may have modest effects on gastrointestinal glucose absorption. The drug does not stimulate insulin secretion, making it weight-neutral and useful across a broad range of glycemic control.","oneSentence":"Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK).","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:48.084Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Prediabetes (prevention of progression to type 2 diabetes)"}]},"trialDetails":[{"nctId":"NCT02616666","phase":"PHASE4","title":"A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2016-08-25","conditions":"Type 2 Diabetes Mellitus","enrollment":632},{"nctId":"NCT02915198","phase":"PHASE4","title":"Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2023-04-03","conditions":"Prediabetic State, Atherosclerosis, Metformin","enrollment":7410},{"nctId":"NCT04029480","phase":"PHASE3","title":"Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-10-08","conditions":"Type 2 Diabetes Mellitus","enrollment":166},{"nctId":"NCT06707012","phase":"PHASE4","title":"Efficacy of Metformin as an Adjunct to Standard Antidepressant Therapy in Treating Depression Among Obese Patients","status":"RECRUITING","sponsor":"Fazaia Ruth Pfau Medical College","startDate":"2025-10-01","conditions":"Depression","enrollment":140},{"nctId":"NCT05349474","phase":"EARLY_PHASE1","title":"Metformin Treatment in Progressive Multiple Sclerosis","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2022-04-26","conditions":"Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis","enrollment":23},{"nctId":"NCT04098666","phase":"PHASE2, PHASE3","title":"Metformin in Alzheimer's Dementia Prevention","status":"ACTIVE_NOT_RECRUITING","sponsor":"Columbia University","startDate":"2021-03-22","conditions":"Mild Cognitive Impairment","enrollment":326},{"nctId":"NCT04741945","phase":"PHASE2","title":"Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDS","status":"RECRUITING","sponsor":"Kirsten Grønbæk","startDate":"2021-12-13","conditions":"Preleukemia, Myelodysplastic Neoplasm, Cytopenia","enrollment":40},{"nctId":"NCT03503942","phase":"NA","title":"The Pre-Diabetes Interventions and Continued Tracking to Ease-out Diabetes (Pre-DICTED) Program","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"2017-12-30","conditions":"Pre-diabetes","enrollment":751},{"nctId":"NCT05182970","phase":"PHASE3","title":"Metformin and Prevention of Cardiovascular Events in Patients With Acute Myocardial Infarction and Prediabetes (MIMET)","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2021-12-02","conditions":"PreDiabetes, Acute Myocardial Infarction, Non ST Elevation Myocardial Infarction","enrollment":5160},{"nctId":"NCT03737240","phase":"PHASE3","title":"IDegLira HIGH Trial","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-01-15","conditions":"Diabetes Mellitus","enrollment":145},{"nctId":"NCT03877406","phase":"PHASE4","title":"Effect of Empagliflozin on Body Composition and Ketones","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2018-08-01","conditions":"Diabetes Mellitus, Fat; Intolerance, Pancreas","enrollment":200},{"nctId":"NCT02621489","phase":"PHASE4","title":"Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2015-12","conditions":"Atherosclerosis, Diabetes, Restenosis","enrollment":38},{"nctId":"NCT04183868","phase":"PHASE4","title":"Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study)","status":"COMPLETED","sponsor":"University of Catanzaro","startDate":"2016-04","conditions":"Type 2 Diabetes, Cardiovascular Risk Factor","enrollment":26},{"nctId":"NCT05305898","phase":"PHASE3","title":"\"MetCool ACS\"- Metformin \"Cooling\" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"Military Institute od Medicine National Research Institute","startDate":"2022-02-08","conditions":"Acute Coronary Syndrome","enrollment":2000},{"nctId":"NCT03332771","phase":"PHASE3","title":"Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2017-12-01","conditions":"Type 2 Diabetes Mellitus","enrollment":954},{"nctId":"NCT01804049","phase":"PHASE1, PHASE2","title":"Metformin and Muscle in Insulin-resistant Older Veterans","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2014-04-08","conditions":"Prediabetes","enrollment":120},{"nctId":"NCT01648582","phase":"PHASE3","title":"A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-07","conditions":"Type 2 Diabetes Mellitus","enrollment":774},{"nctId":"NCT02791490","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-06-16","conditions":"Type 2 Diabetes Mellitus","enrollment":458},{"nctId":"NCT02630706","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-12-16","conditions":"Type 2 Diabetes Mellitus","enrollment":506},{"nctId":"NCT02532855","phase":"PHASE3","title":"A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-20","conditions":"Type 2 Diabetes Mellitus","enrollment":614},{"nctId":"NCT02881528","phase":"PHASE4","title":"Autoimmune Diabetes Accelerator Prevention Trial","status":"WITHDRAWN","sponsor":"University of Exeter","startDate":"2016-03-30","conditions":"Prediabetic State","enrollment":""},{"nctId":"NCT01755156","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-01-11","conditions":"Type 2 Diabetes Mellitus","enrollment":402},{"nctId":"NCT01717313","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-05","conditions":"Type 2 Diabetes Mellitus","enrollment":329},{"nctId":"NCT02033889","phase":"PHASE3","title":"A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-12-13","conditions":"Type 2 Diabetes Mellitus","enrollment":621},{"nctId":"NCT01682759","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-09-10","conditions":"Type 2 Diabetes Mellitus","enrollment":751},{"nctId":"NCT02411825","phase":"PHASE1","title":"Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-03","conditions":"Type 2 Diabetes Mellitus","enrollment":76},{"nctId":"NCT01958671","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-09","conditions":"Type 2 Diabetes Mellitus","enrollment":461},{"nctId":"NCT00700817","phase":"PHASE3","title":"The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":665},{"nctId":"NCT00819741","phase":"PHASE4","title":"Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":433},{"nctId":"NCT00763451","phase":"PHASE3","title":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-09","conditions":"Diabetes Mellitus, Type 2","enrollment":484},{"nctId":"NCT01541956","phase":"PHASE4","title":"Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-02","conditions":"Type 2 Diabetes","enrollment":3091},{"nctId":"NCT02719756","phase":"PHASE4","title":"Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2","status":"UNKNOWN","sponsor":"Research Clinical Centre of the Russian Railways, JSC","startDate":"2016-04","conditions":"Diabetes Mellitus, Hypoglycemic Episodes","enrollment":100},{"nctId":"NCT00792935","phase":"PHASE2","title":"A Study to Test MK-0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-0941-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-01","conditions":"Type 2 Diabetes Mellitus","enrollment":143},{"nctId":"NCT01759823","phase":"PHASE2, PHASE3","title":"Bone Marrow Derived Stem Cell Transplantation in T2DM","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2012-12","conditions":"Type 2 Diabetes Mellitus","enrollment":30},{"nctId":"NCT01065298","phase":"","title":"Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus-2","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2009-11","conditions":"Type 2 Diabetes Mellitus","enrollment":30},{"nctId":"NCT02040246","phase":"PHASE4","title":"Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China","status":"COMPLETED","sponsor":"RenJi Hospital","startDate":"2009-02","conditions":"Diabetes Mellitus, Type 2","enrollment":107},{"nctId":"NCT00856284","phase":"PHASE3","title":"Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-03","conditions":"Type 2 Diabetes Mellitus","enrollment":2639},{"nctId":"NCT00131664","phase":"PHASE3","title":"Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study)","status":"COMPLETED","sponsor":"Canadian Heart Research Centre","startDate":"2005-09","conditions":"Type 2 Diabetes Mellitus","enrollment":391},{"nctId":"NCT00432276","phase":"PHASE3","title":"Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-01","conditions":"Diabetes Mellitus","enrollment":803},{"nctId":"NCT00684528","phase":"PHASE3","title":"A Double-Blind, Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of the Strategy to Start Patients With Type 2 Diabetes Mellitus on Janumet™ Compared to Metformin","status":"UNKNOWN","sponsor":"Meir Medical Center","startDate":"2008-06","conditions":"Diabetes Type 2","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Metformin up-titration","genericName":"Metformin up-titration","companyName":"Research Clinical Centre of the Russian Railways, JSC","companyId":"research-clinical-centre-of-the-russian-railways-jsc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metformin reduces hepatic glucose production and improves insulin sensitivity, lowering blood glucose levels in type 2 diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}